Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 120.40
Bid: 120.00
Ask: 120.40
Change: -1.60 (-1.31%)
Spread: 0.40 (0.333%)
Open: 120.20
High: 121.60
Low: 120.20
Prev. Close: 122.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks up as protests in China deterred by police

Tue, 29th Nov 2022 08:57

(Alliance News) - The FSTE 100 opened in the green on Tuesday as investors were reassured that civil unrest in China would be short lived amid unyielding action by the authorities.

"Police in China have quashed mass Covid demonstrations for now, helping stocks regain their footing on indices across Asia, setting the tone for a positive open in Europe," said Susannah Streeter at Hargreaves Lansdown.

The FTSE 100 index opened up 64.88 points, 0.9%, at 7,538.90. The FTSE 250 was up 11.98 points, 0.1%, at 19,304.33, while the AIM All-Share was down 1.52 points, or 0.2% at 849.40.

The Cboe UK 100 was up 0.8% at 753.71, the Cboe UK 250 was down 0.2% at 16,700.37, and the Cboe Small Companies was up 0.6% at 13,219.22.

In Europe, the CAC 40 index in Paris was up 0.3% and the DAX 40 in Frankfurt was up 0.1%.

China's major cities of Beijing and Shanghai were blanketed with security in the wake of nationwide rallies calling for political freedoms and an end to Covid lockdowns.

The country's leadership is facing a wave of protest not seen in decades, fuelled by anger over the unrelenting lockdowns as well as deep-rooted frustrations over China's political direction.

With police cars, foot patrols, a network of surveillance cameras, and aided by the icy wind, Beijing authorities appeared to have deterred fresh gatherings.

In semi-autonomous Hong Kong, however, where mass democracy protests erupted in 2019, dozens gathered at the Chinese University to mourn the victims of the Urumqi fire. The demonstrators said Covid restrictions were to blame for hampering rescue efforts of the deadly fire.

As the police cracked down on protesters, stocks in China closed firmly in the green on Tuesday. The Shanghai Composite closed up 2.3%, and the Hang Seng in Hong Kong closed up sharply, ending 5.2% higher.

The Nikkei 225 in Tokyo ended up 0.5% and the S&P/ASX 200 in Sydney closed up 0.3%.

News that China said it would speed up a push to vaccinate people aged 60 and older against Covid-19 also helped to boost Asian stocks and investor confidence elsewhere.

In London, AstraZeneca agreed to acquire Neogene Therapeutics, a clinical stage biotechnology company focused on the discovery, development and manufacturing of T-cell receptor therapies for the treatment of cancer.

AstraZeneca said it will pay up to USD320 million. This will include an initial cash payment of USD200 million upon closing and a further USD120 million, contingent on the meeting of unspecified milestones.

Shares in AstraZeneca were up 0.7%

FTSE 250-listed healthcare sector investor Syncona, which holds an 8% stake in Neogene, said it will receive USD16 million from Astra's initial payment.

Shares in Syncona were up 1.2%.

easyJet reported a "record bounce back" in the year ended September 30, with a sharp rise in annual revenue and a significantly narrowed loss.

The low-cost airline's pretax loss narrowed to GBP208 million from GBP1.04 billion the previous year, as revenue multiplied to GBP5.77 billion from GBP1.46 billion the year prior.

easyJet credited the relaxation of pandemic restrictions and an increase in ancillary products for the revenue rise.

Shares in the airline were down 2.0%.

John Wood Group said its trading in the first ten months of 2022 was in line with its expectations. As a result, the company confirmed its full-year guidance.

It expects annual revenue between USD5.2 billion and USD5.5 billion, with adjusted earnings before interest, tax, depreciation and amortisation around the middle of its guidance range of USD370 million and USD400 million.

The guidance saw John Wood plummet 12% in early morning trade.

Elsewhere, Treatt announced a rise in annual revenue but a fall in profit amid negative impacts from Covid restrictions in China, volatile currency movements, and cost inflation.

In the financial year that ended September 30, the ingredient supplier for the beverage, flavour and fragrance industry reported a pretax profit of GBP16.2 million, down from GBP19.6 million the previous year.

Cost of sales jumped to GBP101.1 million from GBP82.1 million, offsetting revenue which grew to GBP140.2 million from GBP124.3 million.

Shares in Treatt were down 1.6%.

The pound was quoted at USD1.2027 early Tuesday in London, a touch higher from USD1.2025 at the London equities close on Monday. Against the yen, the dollar was trading at JPY138.20, down from JPY138.89.

The euro stood at USD1.0368 shortly after the European equities open on Tuesday morning, lower against USD1.0377 late Monday.

For ING's Francesco Pesole, the key for the US dollar moving forward will be Wednesday's speech by Fed Chair Jerome Powell, in which Pesole sees a "higher likelihood that he will sound hawkish", and US jobs data due on Friday.

This is because this may cause the Fed's "communicated and perceived narrative to drift away from dovish pivot expectations".

Ipek Ozkardeskaya added: "There is still hope that Fed President Jerome Powell talks about slower rate hikes at his speech this week, but again, his words shouldn't be heard halfway through. The Fed is willing to slow the pace of rate hikes to avoid going too far. But if they slow down, it's also because they want to go higher than 5%."

St Louis Federal Reserve President James Bullard affirmed on Monday that he believes the Federal Reserve will need to lift the federal funds rate to at least the bottom of a 5% to 7% range.

The benchmark rate is currently 3.75% to 4.00%.

Bullard's hawkishness was echoed by European Central Bank President Christine Lagarde who also signalled further interest rate hikes to come to come on Monday.

"I would like to see inflation having peaked in October but I'm afraid that I would not go as far as that," Lagarde told European lawmakers in Brussels.

Lagarde said the ECB has been hiking "at the fastest pace ever" and that more increases would be needed to bring inflation back down to the ECB's two-percent target.

"We still have a way to go and we're not done with inflation so, yes, we will continue to raise interest rates," Lagarde said.

Gold fetched USD1,752.70 an ounce, higher against USD1,743.16. Brent oil was quoted at USD85.35 a barrel early Tuesday, up from USD82.84 late Monday.

Still to come on Tuesday, there's a provisional CPI reading from Germany at 1300 GMT.

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
11 Apr 2024 14:22

Syncona agrees to sell stake in investee company for GBP7.4 million

(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc.

Read more
4 Apr 2024 17:06

IN BRIEF: Syncona notes investee Achilles's annual loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles.

Read more
14 Mar 2024 14:16

Syncona portfolio company Autolus posts widened loss for 2023

(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses.

Read more
12 Feb 2024 18:01

IN BRIEF: Freeline shareholders approve Syncona acquisition

Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona.

Read more
8 Feb 2024 13:45

UPDATE: Syncona portfolio strengthens thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes.

Read more
8 Feb 2024 09:41

Syncona portfolio strengthens in third quarter thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies.

Read more
8 Feb 2024 09:04

Syncona NAV grows in Q3

(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its portfolio to enable the delivery of key inflection points.

Read more
22 Jan 2024 12:19

IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Read more
19 Jan 2024 08:36

Syncona says Freeline trial for Gaucher disease treatment positive

(Alliance News) - Syncona Ltd on Friday noted Freeline Therapeutics Holdings PLC's positive data for Gaucher disease treatment.

Read more
4 Dec 2023 09:37

IN BRIEF: Syncona notes Beacon's "encouraging" AGTC-501 trial data

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company, Beacon Therapeutics has presented three-month data from the phase 2 Skyline trial of its viral vector-based gene therapy AGTC-501 in X-linked retinitis pigmentosa at the Floretina ICOOR 2023 Congress in Rome. Notes AGTC-501 shows an "encouraging efficacy profile", showing a "significant improvement" in retinal sensitivity. Adds that there are no clinically significant safety events related to AGTC-501.

Read more
27 Nov 2023 19:03

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
22 Nov 2023 14:30

IN BRIEF: Syncona agrees to buyout deal with Freeline Therapeutics

Syncona Ltd - London-based investor in healthcare companies - Agrees to acquire all remaining stock in investee Freeline Therapeutics Holdings PLC for USD6.50 in cash per share, valuing Freeline at approximately USD28.3 million. Syncona currently owns 49.7% of shares in Freeline. The company will provide up to USD15 million of financing in conjunction with the acquisition to enable Freeline to meet its near-term cash requirements and continue advancing its lead programme FLT201, a potential gene therapy for Gaucher disease.

Read more
16 Nov 2023 10:34

Syncona reports declining asset value as investment head steps down

(Alliance News) - Syncona Ltd on Thursday said net asset value decreased as it swung to a negative return in its latest half year, but that it is well-positioned for future growth thanks to its "rich pipeline".

Read more
16 Nov 2023 08:44

Syncona net asset value falls, co-founder steps down

(Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2% during the period.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.